Key Highlights
- Johnson & Johnson to acquire Shockwave Medical for approximately $13.1 billion, aiming to expand its cardiovascular MedTech portfolio.
- The acquisition enhances Johnson & Johnson’s leadership in cardiovascular intervention by adding Shockwave’s intravascular lithotripsy (IVL) technology.
- Shockwave’s IVL technology offers a minimally invasive treatment for calcified arterial lesions, advancing patient care in coronary and peripheral artery disease.
Source: Business Wire
Notable Quotes
- “The acquisition of Shockwave…provides a unique opportunity to accelerate our impact in cardiovascular intervention.” – Joaquin Duato, Chairman and CEO at Johnson & Johnson
- “Shockwave offers a truly differentiated opportunity to further enhance our leadership position in medtech…” – Tim Schmid, EVP and Worldwide Chairman at Johnson & Johnson MedTech
- “As part of a larger, more diverse organization…we are confident we will be able to further solidify IVL as the global standard of care.” – Doug Godshall, President and CEO at Shockwave
SoHC's Take
The acquisition of Shockwave by Johnson & Johnson marks a significant step in the evolution of cardiovascular treatment. With Shockwave’s innovative intravascular lithotripsy technology, Johnson & Johnson not only expands its reach into the fast-growing cardiovascular intervention sector but also reinforces its commitment to providing advanced, minimally invasive treatments for patients worldwide. This move is in line with Johnson & Johnson’s strategy to invest in high-growth markets and technologies that promise to transform patient care, particularly in areas of critical unmet need. The addition of Shockwave to Johnson & Johnson’s MedTech division is poised to drive significant value for patients and stakeholders, setting a new standard in the treatment of complex calcified arterial diseases.
